As of 2025-12-16, the EV/EBITDA ratio of Prometheus Biosciences Inc (RXDX) is -58.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Prometheus's latest enterprise value is 9,445.47 mil USD. Prometheus's TTM EBITDA according to its financial statements is -161.61 mil USD. Dividing these 2 quantities gives us the above Prometheus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 15.1x | 13.6x |
| Forward P/E multiples | 15.5x - 21.8x | 18.6x |
| Fair Price | (50.02) - (48.67) | (52.22) |
| Upside | -125.0% - -124.3% | -126.1% |
| Date | EV/EBITDA |